STIM vs. CLPT, SIBN, BVS, AVNS, ZIMV, BFLY, KIDS, TMCI, SMLR, and CBLL
Should you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include ClearPoint Neuro (CLPT), SiBone (SIBN), Bioventus (BVS), AVANOS MEDICAL (AVNS), ZimVie (ZIMV), Butterfly Network (BFLY), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Semler Scientific (SMLR), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry.
Neuronetics vs. Its Competitors
ClearPoint Neuro (NASDAQ:CLPT) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.
30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 6.1% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 9.8% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, ClearPoint Neuro had 4 more articles in the media than Neuronetics. MarketBeat recorded 4 mentions for ClearPoint Neuro and 0 mentions for Neuronetics. ClearPoint Neuro's average media sentiment score of 0.32 beat Neuronetics' score of 0.00 indicating that ClearPoint Neuro is being referred to more favorably in the media.
Neuronetics has a net margin of -43.47% compared to ClearPoint Neuro's net margin of -66.15%. ClearPoint Neuro's return on equity of -94.44% beat Neuronetics' return on equity.
ClearPoint Neuro has higher earnings, but lower revenue than Neuronetics. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.
ClearPoint Neuro has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
ClearPoint Neuro currently has a consensus target price of $19.67, indicating a potential downside of 25.48%. Neuronetics has a consensus target price of $7.00, indicating a potential upside of 140.55%. Given Neuronetics' higher possible upside, analysts clearly believe Neuronetics is more favorable than ClearPoint Neuro.
Summary
ClearPoint Neuro beats Neuronetics on 9 of the 16 factors compared between the two stocks.
Get Neuronetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuronetics Competitors List
Related Companies and Tools
This page (NASDAQ:STIM) was last updated on 10/8/2025 by MarketBeat.com Staff
